Drug Pricing Negotiation
Expert articles and analysis related to drug pricing negotiation.
AI Summary — Last 30 Days
CMS under the Trump administration is moving drug pricing policy from negotiation rhetoric into benefit-design execution, most notably by launching a Medicare GLP-1 access pathway with a $50 monthly price point—framed as temporary but likely to create durable beneficiary, plan, and provider expectations around obesity pharmacotherapy access and total-cost accountability (Healthcare Finance). At the same time, pressure is building around structural distortions in Part D: Medicare Advantage plans can use MA rebates to subsidize drug premiums and cost sharing, worsening the competitive position of stand-alone PDPs and complicating ACO and payer strategies that rely on stable pharmacy benefit design for population health management (KFF). The near-term strategic tension for VBC stakeholders is whether drug affordability interventions—GLP-1 subsidies, prior authorization interoperability, and potential reference-pricing concepts—lower avoidable downstream spend or simply shift actuarial and utilization risk into Medicare, Medicaid, MA, and accountable care contracts without durable savings.
Related Articles
340B claims data requirements put hospital discounts under stress
Provider advocates criticized Eli Lilly for ramping up pressure on hospitals to comply with a new policy regarding claims submission in the 340B Drug Pricing Program. The drug manufacturer said holdou...
Stretching Scarce Authorizing Legislation as Far as Possible: A Legislative History of the 340B Drug Pricing Program
Stretching Scarce Authorizing Legislation as Far as Possible: A Legislative History of the 340B Drug Pricing Program Milbank Memorial Fund
Behind the Drug Discounts: 340B, Medicare Negotiation, and Transparency
Behind the Drug Discounts: 340B, Medicare Negotiation, and Transparency Health Affairs
The Interaction Between The Manufacturer Discount Program And Medicare Drug Price Negotiation
The Interaction Between The Manufacturer Discount Program And Medicare Drug Price Negotiation Health Affairs
Access, affordability, ambiguity: Who really benefits from federal prescription drug price policies?
CMS officially launches $50 price tag for weight loss drugs in Medicare
Centers for Medicare & Medicaid Administrator Dr. Mehmet Oz has announced the official start of $50-a-month access to GLP-1 medications for Medicare beneficiaries.Oz gave notice of the change during a...
Under the Magnifying Glass: A Wave of Drug Price Transparency
Under the Magnifying Glass: A Wave of Drug Price Transparency AJMC
Eli Lilly to hospitals: Send 340B claims data or lose discounts
Eli Lilly to hospitals: Send 340B claims data or lose discounts Fierce Healthcare
Eli Lilly gives hospitals 5 days to comply with 340B policy
Eli Lilly gives hospitals 5 days to comply with 340B policy Becker's Hospital Review
AHA Statement on Eli Lilly Decision To Move Forward With Policy To Withhold 340B Discounts
AHA Statement on Eli Lilly Decision To Move Forward With Policy To Withhold 340B Discounts American Hospital Association